In this edition:
Interim OS results of abemaciclib in HR+/HER2- advanced breast cancer
Sacituzumab govitecan for HR+/HER2- MBC
Sacituzumab govitecan efficacy by HER2 status
Patient-reported outcomes of trastuzumab deruxtecan
Health-related quality of life with sacituzumab govitecan
Abemaciclib + trastuzumab + fulvestrant for HR+/HER2+ advanced breast cancer
Nivolumab/ipilimumab for TNBC with tumour-infiltrating lymphocytes
HRQoL with neoadjuvant pembrolizumab + chemotherapy for early-stage TNBC
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer
Giredestrant for ER+/HER2- locally advanced/MBC
Amcenestrant for endocrine-resistant ER+/HER2- advanced breast cancer
Elacestrant for ER+/HER2- advanced/ MBC
Please login below to download this issue (PDF)